March 02, 2018
Rose
Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia. It’s the first time a pharma company has made a development deal with a digital therapeutic, according to Pear.
from MobiHealthNews http://ift.tt/2FKYuwa
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment